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Background: Coronavirus disease 2019 (COVID-19) is associated with a high disease burden with 10% of con-
firmed cases progressing towards critical illness. Nevertheless, the disease course and predictors of mortality
in critically ill patients are poorly understood.
Methods: Following the critical developments in ICUs in regions experiencing early inception of the pan-
demic, the European-based, international RIsk Stratification in COVID-19 patients in the Intensive Care Unit
(RISC-19-ICU) registry was created to provide near real-time assessment of patients developing critical ill-
ness due to COVID-19.
Findings: As of April 22, 2020, 639 critically ill patients with confirmed SARS-CoV-2 infection were included in
the RISC-19-ICU registry. Of these, 398 had deceased or been discharged from the ICU. ICU-mortality was
24%, median length of stay 12 (IQR, 521) days. ARDS was diagnosed in 74%, with a minimum P/F-ratio of
110 (IQR, 80148). Prone positioning, ECCO2R, or ECMO were applied in 57%. Off-label therapies were pre-
scribed in 265 (67%) patients, and 89% of all bloodstream infections were observed in this subgroup (n = 66;
RR=3¢2, 95% CI [1¢76¢0]). While PCT and IL-6 levels remained similar in ICU survivors and non-survivors
throughout the ICU stay (p = 0¢35, 0¢34), CRP, creatinine, troponin, D-dimer, lactate, neutrophil count, P/F-
ratio diverged within the first seven days (p<0¢01). On a multivariable Cox proportional-hazard regression
model at admission, creatinine, D-dimer, lactate, potassium, P/F-ratio, alveolar-arterial gradient, and ischemic
heart disease were independently associated with ICU-mortality.
Interpretation: The European RISC-19-ICU cohort demonstrates a moderate mortality of 24% in critically ill
patients with COVID-19. Despite high ARDS severity, mechanical ventilation incidence was low and associ-
ated with more rescue therapies. In contrast to risk factors in hospitalized patients reported in other studies,
the main mortality predictors in these critically ill patients were markers of oxygenation deficit, renal and
microvascular dysfunction, and coagulatory activation. Elevated risk of bloodstream infections underscores
the need to exercise caution with off-label therapies.
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In December 2019, a cluster of atypical severe pneumonia was
described in Wuhan, China, associated with the Huanan Seafood
Wholesale Market [1]. The World Health Organization (WHO)
named the novel virus associated with acute respiratory distress
syndrome (ARDS) as severe acute respiratory syndrome coronavirus
Research in context
Evidence before this study
We performed a PubMed search through April 22, 2020 with no
date or language limitations using the keywords (“COVID-1900
or “SARS-CoV-200) and “cohort” and “characteristics”. Baseline
characteristics of hospitalized patients were reported in regions
such as China, Northern Italy or specific areas in the United
States. Two studies that applied multivariable modeling of risk
factors for mortality and severe disease in hospitalized patients,
respectively, were recently reported in China.
Added value of this study
We report results from a prospective European cohort of critically
ill patients due to COVID-19. The data include the evaluation of
clinical, physiological, and laboratory parameters collected on a
daily basis, as well as intensive care unit mortality. Our findings
accurately characterize severe cases of COVID-19 and identify pre-
dictors of mortality at the onset of critical illness.
Implications of all the available evidence
The in-depth characterization of critically ill COVID-19 patients
and predictors of treatment outcome presented here comple-
ment data from other cohorts to provide crucial information for
decision-making during this exceptional public health crisis.
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(COVID-19) [2]. COVID-19 is a symptomatically and asymptomati-
cally transmissible disease, with a presumed incubation period of up
to 14 days. During the first months of 2020, a rapid global increase in
case numbers and deaths have made this pandemic one of the most
critical global health emergencies in modern times [3]. Approxi-
mately 10% of confirmed cases progress to critical illness [4,5] with
acute lung failure and, in some cases, multi-organ failure involving
the heart, kidney, and gastrointestinal tract, with a high mortality
rate [6]. Reported predisposing factors for severe disease include
older age, chronic arterial hypertension, and established cardiovascu-
lar disease; an underlying virally-triggered endotheliitis has been
postulated as a pathophysiological mechanism [48]. Nevertheless,
whilst epidemiological data on critically ill patients have been well
described, the understanding of disease progression and indicators
for mortality in critical ill patients remains scarce.
Following the critical spread of the disease in China, Italy and Spain,
on March 13, 2020 the European-based RIsk Stratification in COVID-19
patients in the ICU (RISC-19-ICU) registry was launched to allow near-
real time assessment of the main clinical characteristics of critically ill
patients during the emerging COVID-19 pandemic. Understanding
patient characteristics associated with severe forms of COVID-19 is cru-
cial not only for triage and therapeutic selection in these critically ill
patients, but also to generate hypotheses based on the pathophysiology
of the disease and to support the design of further trials.
In the present study, we report the baseline characteristics and sta-
tus at ICU admission of the first 639 European patients with confirmed
COVID-19 included in the RISC-19-ICU prospective cohort. Disease pro-
gression through the initial seven days of intensive care unit (ICU) stay
and prognostic factors for ICU mortality are presented for the 398
patients that had completed their ICU stay as of April 22, 2020.
2. Materials and methods
This prospective observational cohort study is based on the data
collected in the RISC-19-ICU registry. The registry was deemedexempt from the need for additional ethics approval and patient
informed consent by the ethics committee of the University of Zurich
(KEK 202000,322, ClinicalTrials.gov Identifier: NCT04357275). The
study complies with the Declaration of Helsinki, the Guidelines on
Good Clinical Practice (GCP-Directive) issued by the European Medi-
cines Agency as well as the Swiss law and Swiss regulatory authority
requirements, and has been designed in accordance with the
Strengthening the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) guidelines for observational studies [9]. All collaborat-
ing centres have complied with local legal and ethical requirements.
2.1. Registry structure and data collection
A standardized dataset was prospectively collected during the
ongoing COVID-19 pandemic for all critically ill COVID-19 patients
admitted to the collaborating centres. Inclusion criteria for the RISC-
19-ICU registry were (I) a laboratory confirmed SARS-CoV-2 infection
by nucleic acid amplification according to the WHO-issued testing
guidelines [10], and (II) severe manifestation of COVID-19 requiring
treatment in an ICU or intermediate care unit, defined as a hospital
ward specialized in the care of critically ill patients with the availabil-
ity of organ support therapies including invasive mechanical ventila-
tion and/or non-invasive ventilation. The data was collected through
an anonymized electronic case report form managed by the REDCap
electronic data capture tool hosted on a secure server by the Swiss
Society of Intensive Care Medicine [11]. The registry has been
designed to support a collaborative approach to data analysis by per-
mitting all collaborating centres to request an analysis of the full
dataset after approval of a study protocol by the registry board. Addi-
tionally, code for registry-specific data transformation and statistical
analysis has been made available for collaborative development [12].
As of April 22, 2020, 54 collaborating centres in 10 countries were
contributing to the RISC-19-ICU registry. Data were collected on the
day of ICU admission, and on days one, two, three, five and seven
thereafter. Data contained in the registry included patient character-
istics, treatment modalities and organ support therapies, including
the use of mechanical ventilation, prone positioning, vital parame-
ters, arterial blood gas analyses, and laboratory values such as inflam-
matory, coagulation, renal, liver, cardiac, and other relevant
parameters. Missing values were accounted for but not imputed for
the analysis (Suppl. Tables 1 and 2).
2.2. Clinical definitions
ARDS was defined according to the Berlin definition as acute, dif-
fuse bilateral lung infiltrates of non-cardiac origin, characterized by
hypoxemia with a PaO2/FiO2 ratio (P/F ratio)  300 mmHg under pos-
itive pressure respiratory support (5cmH2O positive end-expiratory
airway pressure or continuous positive airway pressure) [13]. Acute
kidney injury was diagnosed in accordance with the KDIGO criteria
as either a serum creatinine increase to more than 1.5 x the baseline
value, an absolute creatinine increase of  26.5 mmol/l, or a urine
output of less than 0.5 ml/kg/h for 612 h [14]. Acute cardiac injury
was defined according to the Fourth Universal Definition of Myocar-
dial Infarction, as an elevation in high sensitivity cardiac Troponin
levels above the 99th percentile, coupled to the existence of a
dynamic change in said levels [15]. Bacteraemia and fungaemia were
defined as positive blood cultures for a bacterial or fungal pathogen.
2.3. Statistical analysis
For longitudinal analysis of clinical and laboratory parameters,
differences between time points and outcome status were tested
using linear mixed effects model analysis. As independent variable
fixed effects, time point and outcome status were entered into the
model, respectively, with and without interaction terms, which were
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dom effects, intercepts for subjects as well as per-subject random
slopes for the effect on dependent variables were employed. P values
were calculated using a likelihood ratio test of the full model with
the effect in question against a “null model” without the effect in
question. P values for individual fixed effects were obtained by Sat-
terthwaite approximation in a multi-dimensional model comprising
time point and outcome status. In patients that have died in the ICU
or were discharged from the ICU, the prognostic value to dichotomize
ICU survival according to the study variables was analysed using uni-
variable and multivariable Cox proportional hazard models; non-nor-
mally distributed variables were logarithmically transformed.
Multivariable analysis was performed by means of an iterative, step-
wise, maximum likelihood optimizing algorithm initiated with the
seven most significant variables in the univariable analysis, and con-
sidering all variables with p<0¢1 on the univariable analysis, for the
final model. Effects of sample size reduction on hazard ratios due to
missing values were considered by comparison of the final model to
a model excluding the respective variable. Censoring was applied to
ICU survivors at the time of discharge to account for the possibility of
an unfavorable outcome during the further hospitalization. Receiver
operating characteristics (ROC) analysis was employed alongside
minimal Euclidean distance fitting to the (0, 1) point to determine
the optimal cut-off values for variables included in the final model.
ICU survival functions were generated by implementing the Kaplan-
Meier estimator. Comparisons of population characteristics were per-
formed using paired Student’s t-test or Wilcoxon Signed Rank Test, as
appropriate, and the chi-squared test for categorical variables. Due to
the observational, prospective nature of this cohort study during the
ongoing health crisis, no power calculations were performed. Statisti-
cal analysis was performed through a fully scripted data management
pathway using the R environment for statistical computing version
3¢6 0¢1 [16]. A two-sided p<0¢05 was considered statistically signifi-
cant. Values are given as median with interquartile ranges or counts
and percentages as appropriate.
2.4. Data statement
Any intensive care unit or other center treating critically ill
COVID-19 patients is invited to join the RISC-19-ICU registry at
https://www.risc-19-icu.net. While the registry protocol prevents
the deposition of the full registry dataset in a third-party repository,
analyses on the full dataset may be requested by any collaborating
center after approval of the study protocol by the registry board.
Reproducibility of the results in the present study was ensured by
providing code for registry-specific data transformation and statisti-
cal analysis for collaborative development on the GitHub and Zenodo
repositories [12]. The registry protocol and data dictionary is publicly
accessible at https://www.risc-19-icu.net.
2.4.1. Role of the funding source
The funders had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of the data;
preparation, review, or approval of the manuscript; and decision to
submit the manuscript for publication.
3. Results
3.1. Population characteristics
As of April 22, 2020, a total of 639 critically ill patients with
COVID-19 admitted to European collaborating centres had been
included in the RISC-19-ICU registry. The patients were 63 [5371]
years old, predominantly male (75¢1%), and 315 (49¢3%) had one or
more comorbidities (Table 1). The first symptoms of SARS-CoV-19
infection were noted 7 [49] days before hospital admission, and thepatients were hospitalized 1 [03] days before admission to the ICU.
At ICU admission, 317 (49¢6%) patients were intubated and 326
(51¢0%) met ARDS diagnosis criteria, with a P/F ratio of 136 [90194]
mmHg and inspiratory oxygen fraction of 60 [4480]% (Table 2). As
of April 22, 2020, 301 patients had been discharged from and 97 had
died in the ICU, resulting in an ICU mortality of 24¢3%; ICU length of
stay was 12 [521] days (Table 3). In 24 (24¢7%) of all non-survivors,
death was secondary to a failure to stabilize acute organ dysfunction,
while life support was withdrawn in 73 non-survivors. The mortality
rate in ARDS patients was 31% and not correlated to initial disease
severity. Population characteristics (Table 1), organ function, and lab-
oratory values at ICU admission (Table 2) were stratified by ICU mor-
tality.
3.2. ICU management
Of the 398 patients discharged from the ICU or who died, 274
(68¢8%) patients were mechanically ventilated (Table 3). The mortal-
ity rate in these patients was 32%. There was no difference in mortal-
ity between patients intubated upon ICU admission versus those
intubated at a later stage (Suppl. Figure 1). ARDS was diagnosed in
293 (73¢6%) patients, with 131 (32¢9%) presenting severe ARDS. The
lowest median P/F ratio in the cohort was 110 [80148] mmHg dur-
ing the initial seven days of ICU treatment (Table 3). Prone position-
ing was applied in 189 (47¢5%) patients at least once during the ICU
stay, further 28 (7¢0%) and 11 (2¢8%) patients underwent ECCO2R and
ECMO therapy, respectively. Vasopressors were prescribed in 236
(68¢8%) patients during their ICU stay. Acute circulatory failure
occurred in 92 (23¢1%) patients, resulting in death in 52% of cases. A
total of 114 (28¢6%) and 23 (5¢8%) patients suffered acute kidney and
acute cardiac injury, respectively; 54 (13¢6%) required renal replace-
ment therapy. 16 (17¢4%) of the 92 patients with acute circulatory
failure suffered acute cardiac injury, of which 11 died and one of
them received ECMO therapy.
Regarding co-infections, 66 (16¢6%) patients had positive blood
cultures for bacteria and eight patients developed fungaemia. In 265
(66¢6%) patients, off-label and compassionate use therapies against
COVID-19 were prescribed, and 160 (60¢4%) of these patients
received a combination of more than one treatment, with hydroxy-
chloroquine and ritonavir/lopinavir being the most frequent (236
(89¢1%) and 112 (43¢3%) patients). Notably, all but ten (89¢1%)
patients with bloodstream infections with bacteria or fungi were
undergoing treatment with off-label therapies, representing a risk
ratio (RR) of 3¢2 with a 95% confidence interval (CI) of 1¢7  6¢0 (p <
0¢001). Corticosteroid and tocilizumab administration was associated
with bloodstream infection in 43 (56¢6%; RR = 4¢2, 95% CI [2¢2  8¢0],
p < 0¢0001), and hydroxychloroquine in 23 (30¢2%; RR = 1¢3, 95% CI
[0¢6  2¢6], p = 0¢475) cases, seven of which were fungaemias.
3.3. Disease course through the first seven ICU days
Levels of Interleukin-6 (IL-6), C-reactive protein (CRP), procalcito-
nin (PCT) levels and white blood cell (WBC) count increased over
time, peaking between days two and three (Fig. 1A - B, Suppl. Table
3). In ICU non-survivors, the WBC count was persistently higher dur-
ing the first seven days of ICU stay (p<0¢01). No difference in initial
IL-6 (p = 0¢70) and CRP (p = 0¢41) levels was observed; however, ICU
non-survivors were characterized by rising CRP dynamics after ICU
admission (p<0¢001). The neutrophil to lymphocyte ratio was persis-
tently higher in ICU non-survivors (p<0¢001, Fig. 1A, Suppl. Table 3).
Platelet count increased in all patients, with ICU survivors presenting
consistently higher counts during the first seven days (p<0¢001,
Fig. 1A, Suppl. Table 3). D-Dimer (p = 0¢01) and lactate dehydrogenase
(LDH) (p<0¢01) levels remained elevated in patients with unfavorable
outcome (Fig. 1A, D, Suppl. Table 3). Overall organ dysfunction
assessed with the Sequential Organ Failure Assessment (SOFA) score,
Table 1
Patient characteristics at ICU admission.
Overall ICU survivor ICU non-survivor p
n = 639 n = 301 n = 97
Demographics
Age, years 63 [53 - 71] 62 [54 - 70] 71 [62 - 78] <0¢001
Age stratification <0¢001
<18 7 (1¢1) 1 (0¢3) 0 (0¢0)
1830 46 (7¢2) 2 (0¢7) 1 (1¢0)
3140 21 (3¢3) 16 (5¢3) 1 (1¢0)
4150 63 (9¢9) 39 (13¢0) 3 (3¢1)
5160 138 (21¢6) 71 (23¢6) 16 (16¢5)
6170 191 (29¢9) 103 (34¢2) 27 (27¢8)
7180 139 (21¢8) 55 (18¢3) 37 (38¢1)
8190 32 (5¢0) 12 (4¢0) 12 (12¢4)
>90 1 (0¢2) 1 (0¢3) 0 (0¢0)
Sex, male 447 (75¢1) 231 (76¢7) 69 (71¢1) 0¢327
BMI, kg m-2 27¢7 [25¢2 - 31¢1] 27¢8 [25¢3 - 31¢2] 27¢8 [25¢0 - 30¢5] 0¢589
Health care workers 21 (3¢6) 14 (4¢7) 2 (2¢1) 0¢424
Smoking status 0¢298
Never Smoked 327 (67¢3) 181 (60¢1) 47 (48¢5)
Smoker or previous smoker 159 (32¢7) 74 (24¢6) 28 (28¢9)
ICU-admission from 0¢629
Emergency room 148 (31¢0) 74 (24¢6) 30 (30¢9)
Normal ward 182 (38¢1) 101 (33¢6) 31 (32¢0)
IMC 68 (14¢2) 26 (8¢6) 7 (7¢2)
Other ICU 80 (16¢7) 32 (10¢6) 14 (14¢4)
Time from symptoms onset to hospitalization, days 7 [4 - 9] 7 [4 - 9] 5 [3 - 7] 0¢099
Time from hospitalization to ICU admission, days 1 [0 - 3] 1 [0 - 3] 1 [0 - 3] 0¢352
Patients with comorbidities 315 (49¢3) 143 (47¢5) 69 (71¢1) <0¢001
Chronic arterial hypertension 282 (44¢1) 136 (45¢2) 57 (58¢8) 0¢027
Ischemic heart disease 81 (12¢7) 34 (11¢2) 21 (21¢6) 0¢016
Other heart disease 71 (11¢1) 31 (10¢3) 20 (20¢6) 0¢014
Diabetes mellitus 147 (23¢0) 70 (23¢3) 31 (32¢0) 0¢114
Chronic pulmonary disease 80 (12¢5) 39 (13¢0) 18 (18¢6) 0¢229
Immunosuppression 73 (11¢4) 30 (10¢0) 21 (21¢6) 0¢005
Country 0¢001
Switzerland 455 (71¢2) 204 (67¢8) 58 (59¢8)
Spain 64 (10¢0) 36 (12¢0) 16 (16¢5)
Italy 35 (5¢5) 23 (7¢6) 1 (1¢0)
France 30 (4¢7) 21 (7¢0) 8 (8¢2)
Germany 25 (3¢9) 9 (3¢0) 5 (5¢2)
Others 30 (4¢6) 8 (2¢7) 9 (9¢3)
Values are given as median [IQR] or count (percent) as appropriate. Health care workers include nurses and physicians who were
after infection with SARS-CoV-2 admitted to an ICU as patients. BMI, body mass index; IMC, intermediate care unit; ICU, intensive
care unit.
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diverged after day one and remained consistently worse in ICU non-
survivors (p<0¢0001) (Fig. 2E, Suppl. Table 3). The course of arterial
lactate levels (p<0¢0001) and pH (p<0¢0001) further distinctly differ-
entiated patients between non-survivors and survivors (Fig. 2D, C,
Suppl. Table 3). Pulmonary function, as measured by the P/F ratio
(p<0¢0001) and the alveolar-arterial gradient (p<0¢0001), improved
within the first week in ICU survivors as opposed to non-survivors
(Fig. 2C, Suppl. Table 3). Troponin T was substantially elevated in ICU
non-survivors (p = 0¢01). Creatinine levels remained consistently ele-
vated (p<0¢0001) and diverged between ICU survivors and non-sur-
vivors after the third day (p<0¢0001, Fig. 2D, E, Suppl. Table 3).
3.4. Prognostic value of patient characteristics at icu admission
In a univariable Cox regression model, crude hazard ratios (HR)
for 27 parameters were associated with an unfavorable ICU outcome
(Suppl. Figure 2). On the multivariable Cox proportional hazard
regression model the following parameters at admission were inde-
pendently associated with ICU mortality: creatinine, D-dimer, lactate,
and potassium levels, P/F ratio and alveolar-arterial gradient, and his-
tory of ischemic heart disease (Fig. 2A). The inclusion of D-dimer lev-
els into the Cox proportional hazards regression model, albeit
reducing final model sample size due to missing values (Suppl. Table
1), resulted in hazard ratios similar to the higher sample size modelwithout D-dimers. Kaplan-Meier survival analysis for all seven
parameters demonstrated a distinction between ICU survivors and
non-survivors for all multivariable independent predictors using the
cut-off values resulting from ROC analyses (Fig. 2B, Suppl. Figure 3).
4. Discussion
This prospective, European cohort study provides an initial
description of the baseline characteristics, treatments, and outcome
of critically ill critically ill COVID-19 patients included in the RISC-19-
ICU registry during the peak of the COVID-19 pandemic in early
2020, constituting a near real-time view of a large international
cohort. ICU admission and treatment data point to a systemic disease
characterized by a cytokine and cellular-driven inflammatory and
coagulation activation, severe pulmonary oxygenation deficit, and in
approximately 24% of cases progression to multi-organ failure and
death. Univariable and multivariable Cox proportional hazards
regression modeling identified several prognostic markers for ICU
mortality, most notably markers of oxygenation deficit, renal and
microvascular dysfunction, and coagulatory activation.
In the present study, the demographics and baseline characteris-
tics of patients who became critically ill due to COVID-19 were pre-
dominantly male, middle-aged, and with comorbidities. These
findings are in concordance with previous case series, most of which
had a predominantly regional or national focus [4,5,7,8,17]. The
Table 2
Organ function, vital signs, and laboratory panel at ICU admission.
Overall ICU survivor ICU non-survivor p
At ICU admission n = 639 n = 301 n = 97
Organ function
APACHE II score 16 [8 - 21] 15 [7 - 20] 20 [13 - 24] <0001
SAPS II score 53 [32 - 68] 51 [32 - 66] 67 [46 - 75] <0001
SOFA score 9 [6 - 13] 9 [6 - 12] 10 [7 - 13] 0190
Need for vasopressors 160 (25¢0) 62 (20¢2) 27 (27¢8) 0¢123
Norepinephrine,mg kg1 min1 0 [0 - 0¢04] 0 [0 - 0¢03] 0 [0 - 0¢08] 0¢015
Respiratory support 0¢002
Nasal Cannula 66 (10¢3) 43 (14¢3) 8 (8¢2)
Mask 89 (13¢9) 54 (17¢9) 17 (17¢5)
High flow oxygen therapy 25 (3¢9) 17 (5¢6) 4 (4¢1)
NIV 27 (4¢2) 12 (4¢0) 9 (9¢3)
Mechanical ventilation 317 (49¢6) 135 (44¢9) 58 (59¢8)
ARDS diagnostic criteria fulfilled 326 (51¢0) 142 (47¢2) 64 (66¢0) 0¢648
Mild 38 (11¢0) 18 (6¢0) 9 (9¢3)
Moderate 179 (52¢0) 74 (24¢6) 38 (39¢2)
Severe 109 (31¢7) 50 (16¢6) 17 (17¢5)
FiO2, % 60 [44 - 80] 60 [40 - 90] 65 [50 - 80] 0¢387
P/F ratio, mmHg 136 [90 - 194] 139 [91 - 202] 131 [85 - 192] 0¢214
A-a gradient, mmHg 358 [246 - 514] 360 [226 - 516] 361 [277 - 517] 0¢407
Ventilatory ratio, ml mmHg kg1 min1 1¢66 [1¢32 - 2¢06] 1¢61 [1¢31 - 2¢05] 1¢64 [1¢36 - 2] 0¢702
ROX index 7¢06 [4¢86 - 9¢87] 6¢86 [4¢90 - 10¢01] 6¢85 [4¢56 - 9¢53] 0¢665
Glasgow coma scale 15 [3 - 15] 15 [3 - 15] 15 [3 - 15] 0¢075
Estimated urine output 0¢001
Normal 488 (85¢3) 266 (88¢4) 74 (76¢3)
Oliguric 64 (11¢2) 27 (9¢0) 15 (15¢5)
Anuric 20 (3¢5) 5 (1¢7) 8 (8¢2)
Vitals
Mean arterial pressure, mmHg 81 [71 - 92] 85 [72¢75 - 94] 75 [69 - 86] 0¢002
Heart rate, min1 86 [75 - 99] 85 [74 - 97] 87 [75 - 99] 0¢735
Respiratory rate, min1 23 [19 - 28] 22 [19 - 28] 24 [19 - 27] 0¢758
Temperature, °C 37¢4 [37¢0 - 38¢4] 37¢3 [37¢0 - 38¢2] 37¢4 [36¢4 - 38¢0] 0¢151
Laboratory panel
Sodium, mmol/l 137 [134 - 140] 137 [134 - 139] 137 [134 - 141] 0¢214
Potassium, mmol/l 3¢9 [3¢6 - 4¢3] 3¢9 [3¢5 - 4¢2] 4¢1 [3¢6 - 4¢6] 0¢011
Hematocrit, % 38 [34 - 42] 37 [33 - 40] 40 [36 - 42] 0¢398
Arterial pH 7¢42 [7¢35 - 7¢46] 7¢43 [7¢36 - 7¢47] 7¢40 [7¢30 - 7¢44] <0¢001
PaO2, kPa 9¢7 [8¢2 - 12¢1] 9¢7 [8¢3 - 12¢4] 9¢9 [8¢2 - 12¢1] 0¢738
PaCO2, kPa 4¢9 [4¢2 - 5¢9] 4¢8 [4¢2 - 5¢6] 5¢0 [4¢2 - 6¢1] 0¢204
Arterial HCO3, mmol/l 23¢5 [21¢4 - 25¢9] 23¢7 [21¢9 - 25¢8] 22¢9 [20¢6 - 24¢6] 0¢007
Arterial lactate, mmol/l 1¢2 [0¢9 - 1¢5] 1¢1 [0¢8 - 1¢5] 1¢3 [1¢0 - 1¢8] 0¢005
White blood cell count, 109/l 7¢8 [5¢6 - 10¢7] 7¢4 [5¢3 - 10¢2] 8¢0 [6¢1 - 11¢6] 0¢024
Neutrophil count, 109/l 6¢4 [4¢4 - 9¢3] 6¢0 [4¢1 - 8¢7] 6¢9 [5¢1 - 9¢8] 0¢020
Lymphocyte count, 109/l 0¢75 [0¢51 - 1¢10] 0¢80 [0¢56 - 1¢04] 0¢70 [0¢50 - 1¢10] 0¢331
Neutrophil/ Lymphocyte ratio 8¢1 [5¢1 - 14¢4] 7¢6 [4¢8 - 13¢3] 9¢6 [5¢6 - 16¢2] 0¢061
Thrombocytes, 109/l 205 [161 - 272] 214 [167 - 282] 191 [148 - 247] 0¢024
Interleukin-6, ng/l 142 [50 - 361] 104 [50 - 289] 173 [50 - 381] 0¢703
CRP, mg/l 141 [77 - 221] 136 [76 - 217] 143 [93 - 216] 0¢406
PCT,mg/l 0¢34 [0¢19 - 1¢06] 0¢26 [0¢16 - 0¢76] 0¢45 [0¢20 - 1¢44] 0¢006
D-Dimers,mg/l 1329 [800 - 2813] 1149 [720 - 2034] 1900 [830 - 4620] 0¢016
Ferritin, mg/l 1393 [749 - 2213] 1283 [683 - 2126] 1377 [791 - 2253] 0¢839
LDH, U/l 488 [378 - 679] 465 [364 - 639] 506 [427 - 673] 0¢035
Bilirubin, mmol/l 9 [5 - 14] 10 [5 - 14] 9 [6 - 14] 0¢988
Urea, mmol/l 7¢7 [4¢7 - 19¢1] 6¢5 [4¢0 - 14¢9] 12¢9 [6¢4 - 31¢7] <0¢001
Creatinine,mmol/l 84 [67 - 112] 79 [65 - 99] 88 [71 - 154] 0¢002
CK, U/l 152 [70 - 352] 137 [75 - 262] 160 [66 - 385] 0¢636
Myoglobin,mg/l 93 [45 - 317] 115 [51 - 297] 93 [27 - 938] 0¢925
Troponin, ng/l 18¢0 [10¢0 - 48¢0] 13¢1 [8¢0 - 28¢6] 43¢1 [16¢4 - 96¢0] <0¢001
Albumin, g/l 28 [23 - 32] 28 [23 - 33] 27 [23 - 30] 0¢226
Values are given as median [IQR] or count (percent) as appropriate. APACHE II, Acute Physiology And Chronic Health Evalu-
ation II; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; ARDS, Acute Respiratory
Distress Syndrome; NIV, non-invasive ventilation; FiO2, fraction of inspired O2; P/F ratio, PaO2/ FiO2 ratio; A-a gradient,
alveolo-arterial gradient; PaO2, partial pressure of arterial O2; PaCO2, partial pressure of arterial CO2; CRP, c-reactive pro-
tein, PCT, procalcitonin; LDH, lactate dehydrogenase; CK, creatine kinase.
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than that reported in other critically ill COVID-19 populations to date
[4,5,7,17]. Nevertheless, the incidence of mechanical ventilation in
our cohort was lower than that reported in case series from Northern
Italy and the United States [7,18]. By contrast, a considerably higher
proportion of patients in our cohort received rescue therapies includ-
ing prone positioning, inhaled nitric oxide and extracorporeal decar-
boxylation and oxygenation. These differences may reflect the largevariability in therapeutic approaches applied in our cohort related to
the international scope of this study. Given the relatively low mortal-
ity rate in our compared to other reports [4,5,7,8,17,19], together
with the lack of clear evidence regarding the optimal respiratory
management of critically ill COVID-19 patients, our findings suggest
that a wide range of therapeutic approaches—which reflect the par-
ticular expertise of the participating hospitals—could be successful
strategies in treating critically ill COVID-19 patients. In ICU non-
Table 3
Organ support, ICU treatment and adverse events within the first seven days of the ICU stay.
ICU Outcome Only ICU survivor ICU non-survivor p
n = 398 n = 301 n = 97
Organ support
Maximal respiratory support <0¢001
Mask 74 (19¢9) 66 (21¢9) 8 (8¢2)
High flow oxygen therapy 10 (2¢5) 10 (3¢3) 0 (0¢0)
NIV 12 (3¢2) 9 (3¢0) 3 (3¢1)
Mechanical ventilation 274 (68¢8) 188 (62¢5) 86 (88¢7)
Lowest P/F ratio in initial 7 days, mmHg 110 [80 - 148] 113 [84 - 153] 94 [71 - 127] 0¢001
Worst ARDS classification in initial 7 days 0¢372
Mild 6 (1¢5) 5 (16¢6) 1 (1¢0)
Moderate 131 (32¢9) 94 (31¢2) 37 (38¢1)
Severe 131 (32¢9) 83 (27¢6) 48 (49¢5)
Need for vasopressors 236 (68¢8) 161 (53¢5) 75 (77¢3) 0¢001
Highest norepinephrine levels in initial 7 days,mg kg1 min1 0¢03 [0 - 0¢14] 0¢02 [0 - 0¢10] 0¢12 [0¢02 - 0¢27] <0¢001
Hemodialysis 54 (13¢6) 34 (11¢3) 20 (20¢6) 0¢031
Rescue therapies
Prone positioning 189 (47¢5) 129 (42¢9) 60 (61¢9) 0¢002
Extracorporeal CO2 removal 28 (7¢0) 20 (6¢6) 8 (8¢2) 0¢758
ECMO 11 (2¢8) 7 (2¢3) 4 (4¢1) 0¢560
Inhaled nitric oxide 6 (1¢5) 3 (1¢0) 3 (3¢1) 0¢320
Adverse events
ARDS 293 (73¢6) 203 (67¢4) 90 (92¢8) <0¢001
Acute kidney injury 114 (28¢6) 62 (20¢6) 52 (53¢6) <0¢001
Hemodynamic shock 92 (23¢1) 42 (14¢0) 50 (51¢5) <0¢001
Acute cardiac injury 23 (5¢8) 9 (3¢0) 14 (14¢4) <0¢001
Bacteraemia* 66 (16¢6) 46 (15¢3) 20 (20¢6) 0¢284
Fungaemia* 8 (2¢0) 5 (1¢7) 3 (3¢1) 0¢647
Off-label and compassionate use therapies
No experimental therapies 133 (33¢4) 102 (33¢9) 31 (32¢0) 0¢726
Chloroquine/ Hydroxychloroquine 236 (59¢3) 178 (59¢1) 58 (59¢8) 1¢000
Lopinavir/ Ritonavir 112 (28¢1) 85 (28¢2) 27 (27¢8) 1¢000
Corticosteroids 66 (16¢6) 43 (14¢3) 23 (23¢7) 0¢044
Tocilizumab 71 (17¢8) 59 (19¢6) 12 (12¢4) 0¢143
Remdesivir 23 (5¢8) 18 (6¢0) 5 (5¢2) 0¢958
Other Antivirals 26 (6¢5) 21 (7¢0) 5 (5¢2) 0¢693
Interferon therapy 8 (2¢0) 4 (1¢3) 4 (4¢1) 0¢197
Extracorporeal cytokine adsorption and plasma exchange therapy 4 (1¢0) 0 (0¢0) 4 (4¢1) 0¢003
Intravenous IgG 1 (0¢3) 1 (0¢3) 0 (0¢0) 1¢000
Number of simultaneous experimental therapies 2 [1 - 3] 2 [1 - 3] 2 [1 - 3] 0¢858
Simultaneous use of off-label therapies 0¢869
1 off-label therapy 105 (26¢4) 79 (26¢2) 26 (26¢8)
2 off-label therapies 77 (19¢3) 59 (19¢6) 18 (18¢6)
3 off-label therapies 49 (12¢3) 35 (11¢6) 14 (14¢4)
>3 off-label therapies 34 (8¢5) 26 (8¢6) 8 (8¢2)
Treatment withdrawal and length of stay
Withdrawal of life supporting therapies 73 (18¢3) 0 (0¢0) 73 (72¢3) <0¢001
ICU length of stay, days 12 [5 - 21] 12 [5 - 21] 12 [5 - 21] 0¢782
Values are given as median [IQR] or count (percent) as appropriate. NIV, non-invasive ventilation; P/F ratio, PaO2/ FiO2 ratio; ARDS, acute respi-
ratory distress syndrome; ECMO, extracorporeal membrane oxygenation; IgG, Immunoglobulin G; ICU, intensive care unit. *59 (86¢7%) and 7
(87¢5%) of all bacterial and fungal bloodstream infections developed in patients with off-label therapies.
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found to be similar in this cohort of critically ill COVID-19 patients as
previously described in European ICUs in a non-pandemic setting
[20].
The use of off-label and compassionate use therapies, as well
as the combination of multiple empirical drugs, was common in
the present cohort, a finding that is consistent with other case
series [4,5,19,21]. As evidenced in recent publications, many of
these therapies were initially hypothesized to be effective [22,23]
and broadly adopted, but subsequently failed to show clear evi-
dence of effectiveness [24,25]. In this regard, our findings add to
previous concerns regarding off-label medication, particularly
immunosuppressive therapies [26]. The high incidence of blood-
stream infections in patients treated with off-label therapies in
the present cohort, especially those who received corticosteroids
and IL-6 anti-body therapies, underscore the WHO recommenda-
tion to limit the use of empirical therapies to the controlled set-
ting of clinical trials [27].Recently, it has been postulated that multiple parameters may
have potential prognostic capacity to discern unfavorable outcomes
in general populations of hospitalized COVID-19 patients [4,5,17,28].
The multivariable Cox proportional hazards regression model applied
in the present comparatively large, international patient cohort iden-
tified several independent predictors of mortality in critically ill
COVID-19 patients. While markers of coagulation activation and
microvascular dysfunction such as D-dimer and lactate levels,
together with markers of renal dysfunction, were positively associ-
ated with ICU mortality, an inverse association was found for the P/F
ratio as a measure of oxygenation deficit. These findings support pre-
vious observations of the presence of severe inflammatory reaction
[5] and endothelial dysfunction [6] in these patients, thereby provid-
ing a plausible pathophysiological correlate to the severely decreased
P/F ratio due to alveolar fluid accumulation. This would explain the
initially highly compliant lungs with severely impaired gas diffusion
that is pathognomonic for this disease. [29,30] The persistent inflam-
matory activation and increased recruitment of neutrophils and non-
resolving lymphopenia observed in our study—mainly in non-
Fig. 1. Temporal progression of organ function, vital, and laboratory parameters over the initial seven days of ICU stay. A) Development of blood cell counts and coagulation
markers, (B) inflammatory biomarkers, (C) lung function, (D) circulatory system function and (E) kidney and overall organ function, within the first seven days of ICU treatment of
critically ill patients suffering from COVID-19 stratified by ICU mortality. Lines represent the median values, shaded areas the interquartile range.
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sic non-compliant ARDS phenotype later in the course of disease, as
previously suggested [29]. Even though the systemic pro-inflamma-
tory state observed in the present cohort confirms previous data
[4,5,17], our findings suggest that IL-6 and PCT levels may be less
prognostic than previously proposed [4,17,28]. In the present study,
our focus on severe cases for which outcome data were available for
a high proportion of patients, facilitates the systematic investigation
of pathophysiologic processes. By contrast, most previous reports
have assessed general hospitalized patient populations with only lim-
ited outcome data [4,7]. Ischemic heart disease was the sole predis-
posing condition assessed in this study that retained an association
with ICU mortality on multivariable analysis. Similar D-dimer levels
were found in critically ill patients with or without this predisposingcondition, presenting no obvious link to coagulatory activation. Ische-
mic heart disease has been described in previous studies involving
general hospitalized cohorts, including non-critically ill patients
[31,32], where other conditions such as chronic arterial hypertension,
diabetes mellitus, age, and body mass index were also implicated.
Prognostic analyses that conjointly model non-critically and critically
ill patients to infer hospital mortality without adjusting for disease
severity are ultimately at risk of selection bias. The RISC-19-ICU regis-
try provides the prerequisites for the development of risk scores in
critically ill patients, and due to its collaborative nature the data pre-
sented here could be combined with databases of similar scope for
joint data analysis.
The limitations of the present study pertain mainly to the pro-
spective data collection, which was performed in highly variable
Fig. 2. Risk factors associated with ICU mortality. Prognostication of ICU mortality in a multivariable Cox proportional hazards regression model was visualized in a Forrest plot (A).
Kaplan-Meier analysis of six of the defining model components (creatinine, D-dimer, lactate and potassium levels, the P/F ratio and ischemic heart disease) demonstrate their effect
on ICU mortality over time; patients discharged alive from the ICU are noted as censored (B).
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edented public health crisis. While missing values due to local differ-
ences in laboratory capability or resource availability were present
and could potentially have led to effect over- or underestimation,
efforts were made to mitigate this variability by rigorous monitoring
of data quality and the use of linear mixed model analysis for the
descriptive analysis. Further, lead-time bias was moderated by align-
ment of the data collection time points to the onset of critical diseasestatus. Survival analysis during an ongoing crisis is associated with a
potential survivorship bias in favor of patients with a short ICU length
of stay with potentially more severe cases still residing in the ICU.
However, by including into the outcome analysis only patients that
had already been discharged from the ICU, censoring of the patients
that were discharged from the ICU alive could be applied in the Cox
proportional hazards model to account for the possibility of an unfa-
vorable outcome during the further hospitalization and thus reduce
P.D. Wendel Garcia et al. / EClinicalMedicine 25 (2020) 100449 9the potential for additional bias. While hospital outcomes and follow-
up assessments may be analysed in a future retrospective analysis,
the present study is capable of providing insight during the ongoing
pandemic. Finally, due to the international study design, the resour-
ces, policies and therapeutic approaches utilized in the participating
centres and countries presumably were highly heterogeneous, which
should be considered when interpreting the results presented here.
Correction for clustering was not implemented into the statistical
models to prevent an increased risk of type II error in light of the
reduced number of patients admitted to certain centres at the time
point of analysis as previously described [33]. This heterogeneity,
however, could provide the basis to perform regional or resource-
centered subgroup analyses in the future.
In conclusion, the European RISC-19-ICU cohort demonstrates a
moderate ICU mortality of 24% in critically ill patients with COVID-
19. Despite a high degree of ARDS severity, the incidence of mechani-
cal ventilation was low and associated with a higher proportion of
rescue therapies, which included prone positioning, inhaled nitric
oxide and extracorporeal decarboxylation and oxygenation therapies.
In contrast to previously reported risk factors for mortality in hospi-
talized COVID-19 patients, our findings suggest that only creatinine,
D-dimer, lactate, potassium, P/F ratio and alveolar-arterial gradient at
admission and ischemic heart disease are predictors of mortality in
critically ill patients with COVID-19. The elevated risk of bloodstream
infections associated with empirical therapies, especially corticoste-
roids and tocilizumab, underscores the need to exercise caution with
the use of off-label therapies.
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